Healthcare / BiotechnologyTokyo
$563.00
+46.00 (+8.90%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-1.5B · quality 67.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$25.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
453.0%
↑Gross Margin
N/A
•Debt/Equity
-8.24
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.72x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-2.86B · FCF $-2.05B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Net Income | $-2.86B | $-2.86B | $-2.39B | $-2.00B |
| EBITDA | $-1.93B | $-1.93B | $-1.72B | $-1.61B |
| EPS | — | — | -74.58 | -62.42 |
| Balance Sheet | ||||
| Debt/Equity | -8.24 | -8.24 | -2.13 | -2.03 |
| Current Ratio | 28.49 | 28.49 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $-2.05B | $-2.05B | $-1.31B | $-1.47B |
| Returns | ||||
| ROE | 453.0% | 453.0% | 122.3% | 115.2% |
| Growth & Yield | ||||
| EPS Growth | — | — | -19.5% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-46.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-74.58 → n/d
Residual
-46.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.